An OPEN LABEL Phase II Safety Study of Bovine Intestinal Alkaline Phosphatase (bIAP), an Inflammation Modulating Moiety, in RA Patients.

Trial Profile

An OPEN LABEL Phase II Safety Study of Bovine Intestinal Alkaline Phosphatase (bIAP), an Inflammation Modulating Moiety, in RA Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2015

At a glance

  • Drugs Alkaline phosphatase (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Acronyms REUMAP
  • Sponsors Alloksys Life Sciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jan 2014 Status changed from recruiting to completed.
    • 25 Aug 2011 Planned End Date changed from 5 Apr 2012 to 1 May 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top